• Lead all commercial activities across 3 US business segments and a Canadian affiliate, with full P&L responsibility for approximately $2B in revenue. Acting in a Chief Commercial Officer (CCO) role, successfully delivered 17 consecutive quarters that met or surpassed financial targets. • Serve as a Section 16 Named Executive Officer reporting directly to the CEO while managing 8 direct reports, ~450 personnel, and an OpEx budget of more than $300M annually. Lead the Commercial Operations Leadership team (COLT), comprised of commercial direct reports and an extended leadership team supporting commercial, including medical affairs, legal, corporate affairs, compliance, FP&A, HR, and IT.• Drive the portfolio strategy and guide investment decisions and valuation work for new products, indications, and product planning opportunities. Oversee the Portfolio Review Committee process, which is responsible for all portfolio decision-making and governance, and serve as the primary executive liaison to the Board Portfolio Committee.• Maintain responsibility for 3 Centers of Excellence supporting key operational functions, including managed care, patient support services, value and pricing, trade, forecasting, sales and marketing operations, customer service, portfolio strategy, business development, and lifecycle management.• Stabilized the XIAFLEX franchise, restored growth in the wake of the pandemic, and advanced the development of multiple Life Cycle Management (LCM) projects, which solidified and repositioned the branded segment as a leading growth driver with billion-dollar potential. • Developed and executed a portfolio strategy that transformed the Sterile Injectable Segment. Since 2020, reloaded the pipeline to build a more durable and differentiated portfolio while simultaneously launching approximately 50 new SI and GX products.

• Promoted in recognition of the performance transformation of Branded Pharmaceuticals, which repositioned the segment as a primary growth driver for Endo. Led segment commercial activities and maintained full accountability for a $1B P&L, and exceeded financial targets for the Branded Specialty portfolio for 9 consecutive quarters. • Managed 6 VP-level direct reports, 7 key functions including sales, marketing, patient access, advanced analytics and commercial ops, and had oversight of an annual sales and marketing budget of $250M. Served as Chairperson of the Pharmaceuticals Leadership Team (PLT), a decision-making body responsible for setting the Branded segment’s strategy and developing and executing the annual operations plan. • Developed and launched transformational growth strategies that ignited double-digit growth for three consecutive years, including 11% growth in 2017, 11% growth in 2018, and 17% growth in 2019. Exceeded internal and external portfolio performance expectations for all four quarters of FY 2020. • Built and executed an enterprise-wide launch readiness plan that enabled cross-functional execution, achieved the first and only FDA approved injectable for cellulite, and stood up a new medical aesthetics business unit.

• Led a major strategic transformation of the Branded organization from a legacy concentration on pain management to a highly focused specialty biopharma business. Managed all commercial activities within the branded segment, representing approximately $1B in revenue, and delivered on all financial targets for the organization. Managed 6 direct reports, 7 indirect personnel, and a sales and marketing budget of $200M.• Resurrected XIAFLEX, a mid-life cycle biologic with flat to declining growth, increased revenue by +20% in 2018, and repositioned the product as a key driver of growth with $1B in potential. Revamped the marketing strategy with healthcare professionals, enhanced product acquisition processes with all new trade partnerships, and developed and launched a direct-to-consumer activation capability leveraging broadcast and digital channels.• Championed an engagement and communication strategy that revitalized the culture, improved accountability, enhanced commercial execution, drove performance, and increased sales team engagement to 90%+.• Achieved industry-leading turn-around times and dispense rates by delivering next-level capabilities in HUB patient support services, field reimbursement, and mastered distribution channels.

• Launched the new General Medicines business unit as part of a global reorganization, provided complete commercial oversight for branded businesses in renal, allergy, biosurgery and generic product sales across the US and Canada, led sales and marketing activities, and successfully delivered on financial targets. Managed a team of 7 direct reports and a P&L of $1.8B.

• Selected to take on a newly created role to lead three complex specialty business units, including Oncology, Renal, and Biosurgery, with $2.3B in combined revenues. Led the integration of the BUs into the North American Pharma infrastructure and accelerated their performance. Managed 4 direct reports and 2 indirect resources. • Built an innovative portfolio segmentation and investment strategy, created flexible commercial and investment models, and surpassed budget performance and profit contribution objectives by 106% of plan. • Turned around the Oncology portfolio and achieved double market growth (15%+) for JEVTANA. Protected $800M+ in Renal sales revenue and preserved market leadership. Restored performance in the struggling Biosurgery business unit through a resized sales force and breakthrough product acquisition services.

• Led the overall brand strategy for the division, headed sales and marketing for Multaq and AUVI-Q, and exceeded financial targets for the cardiovascular franchise. Managed a team of 5 direct reports, led sales and brand teams, and maintained an annual P&L responsibility of $400M+.• Managed pre-commercialization and product launch activities for a novel oral anticoagulant (NOACs), PCSK9 inhibitor, a new epinephrine auto-injector, and Sanofi/Regeneron partnered monoclonal antibody products. • Served as the Commercial Leader for Multaq between 2011 and 2012, reshaped the commercial plan for the product and surpassed all revenue goals.